Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Licenses Asuragen's Sample-Preservation Product for Use with MammaPrint

NEW YORK (GenomeWeb News) - Asuragen said today it has granted global rights to Agendia for use of its RNARetain tissue preservation solution for human diagnostic applications.
Under the non-exclusive agreement, Agendia will use RNARetain to store and ship tumor samples for its MammaPrint diagnostic, which predicts the risk of the recurrence of breast cancer.
RNARetain, also known as RNAlater, is used to preserve nucleic acid profiles in solid tissues.
Agendia performs the MammaPrint analysis in its own lab using samples that physicians prepare and ship to its Amsterdam headquarters. According to the company’s website, MammaPrint analysis cannot be performed on formalin-fixed paraffin embedded tumor tissue “as this fixation procedure causes the RNA to degrade.”
Agendia received 510(k) clearance from the US Food and Drug Administration for MammaPrint earlier this year. It was the first assay the agency approved as an in vitro diagnostic multivariate assay since it released a draft guidance concerning the use of such devices last year.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.